ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.65
-0.26%
US Tech 100
19,168.00
0.52%
S&P 500
5,431.60
-0.04%
US Dollar vs CAD
1.37515
-0.01%
Bitcoin
66,152.73
0.23%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. 23andMe Holding Company (ME)

  7. 23andMe Holding Company (ME) News

ME

23andMe (ME)

23andMe Holding Company
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ME
DateTimeSourceHeadlineSymbolCompany
06/10/20243:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
06/05/20246:00AMGlobeNewswire Inc.23andMe Launches New Genetic Report on Bipolar DisorderNASDAQ:ME23andMe Holding Company
06/04/20246:00AMGlobeNewswire Inc.23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black CommunityNASDAQ:ME23andMe Holding Company
06/03/20247:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
06/03/20247:00AMGlobeNewswire Inc.23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual MeetingNASDAQ:ME23andMe Holding Company
05/29/20247:00AMGlobeNewswire Inc.Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and historyNASDAQ:ME23andMe Holding Company
05/24/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
05/23/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
05/23/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
05/23/20243:05PMGlobeNewswire Inc.23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
05/21/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
05/21/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
05/14/20246:00AMGlobeNewswire Inc.Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsNASDAQ:ME23andMe Holding Company
05/10/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
05/09/20243:50PMGlobeNewswire Inc.23andMe to Report Q4 and Full Year FY2024 Financial ResultsNASDAQ:ME23andMe Holding Company
04/30/202410:00AMBusiness WirePotter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseNASDAQ:ME23andMe Holding Company
04/24/20243:05PMGlobeNewswire Inc.23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:ME23andMe Holding Company
04/18/20247:00AMGlobeNewswire Inc.23andMe announces CEO’s intention to pursue a potential take-privateNASDAQ:ME23andMe Holding Company
04/05/20243:05PMGlobeNewswire Inc.23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
03/20/20246:30AMGlobeNewswire Inc.23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6NASDAQ:ME23andMe Holding Company
03/19/20247:00AMGlobeNewswire Inc.23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years AgoNASDAQ:ME23andMe Holding Company
03/06/20246:30AMGlobeNewswire Inc.23andMe Launches New Genetic Reports on Common Forms of CancerNASDAQ:ME23andMe Holding Company
03/05/20243:30PMGlobeNewswire Inc.23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
02/21/20243:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
02/07/20243:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ME23andMe Holding Company
02/07/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
02/07/20243:01PMGlobeNewswire Inc.23andMe Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
02/06/20246:00AMBusiness WireMoneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc.NASDAQ:ME23andMe Holding Company
01/31/20246:50AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
01/30/20249:12PMGlobeNewswire Inc.23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernayNASDAQ:ME23andMe Holding Company
 Showing the most relevant articles for your search:NASDAQ:ME

Your Recent History

USOTC
CNNA
Cann American (CE)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
ERHE
ERHC Energy (CE)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
FNMA
Fannie Mae (QB)
COIN
SHIBUSD
SHIBA INU
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
RXMD
Progressive Care (QB)
NASDAQ
NVDA
NVIDIA
NASDAQ
AVXL
Anavex Life Sciences
USOTC
HHSE
Hannover House (PK)
USOTC
RDGL
Vivos (QB)
USOTC
RNVA
Rennova Health (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved